The Editor’s Roundtable: Revisiting the Role of Beta Blockers in Hypertension

      Dr. Roberts has received honoraria for speaking from Merck, Whitehouse Station, New Jersey; Schering Plough, Kenilworth, New Jersey; Pfizer, New York, New York; AstraZeneca, Wilmington, Delaware; and Novartis, Annandale, New Jersey. Dr. Black has received honoraria for speaking and consulting from Pfizer, Novartis, Bristol-Myers Squibb, New York, New York; Sanofi-Aventis, Bridgewater, New Jersey; Forest, New York, New York; Boehringer-Ingelheim, Ridgefield, Connecticut; Merck, Gilead, Foster City, California; Myogen, and Intercure, Fort Lee, New Jersey. Dr. Bakris has received honoraria for speaking and consulting from AstraZeneca, Abbott, Abbott Park, Illinois; Bristol-Myers Squibb/Sanofi-Aventis, GlaxoSmithKline, Research Triange Park, North Carolina; Merck, Novartis, Lilly, Indianapolis, Indiana; Walgreens, and Myogen. He has received grants from the National Institutes of Health, Abbott, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, and Myogen. Dr. Mason has received investigator-initiated research grants and honoraria for speaking or consulting from sanofi-aventis, Bristol-Myers Squibb, Pfizer, and Forest Laboratories. Dr. Giles has received honoraria for speaking and consulting from Boehringer-Ingelheim, Bristol-Myers Squibb, Sanofi-Aventis, Novartis, Forest Laboratories, and Pfizer. He has received grant funding from Novartis and AstraZeneca. All other individuals in a position to control content disclosed no relevant financial relationships.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Joint National Committee on Detection, Evaluation, and Treatment of High BP
        The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High BP (JNC V).
        Arch Intern Med. 1993; 153: 154-183
        • MRC Working Party
        Medical Research Council trial of treatment of hypertension in older adults: principal results.
        BMJ. 1992; 304: 405-412
        • Dahlof B.
        • Sever P.S.
        • Poulter N.R.
        • Wedel H.
        • Beevers D.G.
        • Caufield M.
        • Collins R.
        • Kjeldsen S.E.
        • Kristinsson A.
        • McInnes G.T.
        • Mehlsen J.
        • Nieminen M.
        • O’Brien E.
        • Ostergren J.
        • ASCOT Investigators
        Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-BP Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
        Lancet. 2005; 366: 895-906
        • Dahlof B.
        • Devereux R.B.
        • Kjeldsen S.E.
        • Julius S.
        • Beevers G.
        • de Faire U.
        • Fyhrquist F.
        • Ibsen H.
        • Kristiansson K.
        • Lederballe-Pedersen O.
        • Lindholm L.H.
        • Nieminen M.S.
        • Omvik P.
        • Oparil S.
        • Wedel H.
        • LIFE Study Group
        Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
        Lancet. 2002; 359: 995-1003
        • Lindholm L.H.
        • Carlberg B.
        • Samuelsson O.
        Should β blockers remain first choice in the treatment of primary hypertension?.
        Lancet. 2005; 366: 1545-1553
        • Chobanian A.V.
        • Bakris G.L.
        • Black H.R.
        • Cushman W.C.
        • Green L.A.
        • Izzo Jr, J.L.
        • Jones D.W.
        • Materson B.J.
        • Oparil S.
        • Wright Jr, J.T.
        • Roccela E.J.
        • National High BP Education Program Coordinating Committee
        The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High BP.
        JAMA. 2003; 289: 2560-2572
        • Rosamond W.
        • Flegal K.
        • Friday G.
        • Furie K.
        • Go A.
        • Greenlund K.
        • Haase N.
        • Ho M.
        • Howard V.
        • Kissela B.
        • Kittner S.
        • Lloyd-Jones D.
        • McDermott M.
        • Meigs J.
        • Moy C.
        • Nichol G.
        • O’Donnell C.J.
        • Roger V.
        • Rumsfeld J.
        • Sorlie P.
        • Steinberger J.
        • Thom T.
        • Wasserthiel-Smoller S.
        • Hong Y.
        • American Heart Association Statistics Committee and Stroke Statistics Subcommittee
        Heart disease and stroke statistics–2007 update.
        Circulation. 2007; 115: e69-e171
        • Hertz R.P.
        • Unger A.N.
        • Cornell J.A.
        • Saunders E.
        Racial disparities in hypertension prevalence, awareness, and management.
        Arch Intern Med. 2005; 165: 2098-2104
        • Kannel W.B.
        Role of BP in cardiovascular disease: the Framingham Study.
        Angiology. 1975; 26: 1-14
        • Multiple Risk Factor Intervention Trial (MRFIT) Research Group
        Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial.
        Prev Med. 1986; 15: 254-273
        • Psaty B.M.
        • Smith N.L.
        • Siscovick D.S.
        • Koepsell T.D.
        • Weiss N.S.
        • Heckbert S.R.
        • Lemaitre R.N.
        • Wagner E.H.
        • Furberg C.D.
        Health outcomes associated with antihypertensive therapies used as first-line agents.
        JAMA. 1997; 277: 739-745
        • Neal B.
        • MacMahon S.
        • Chapman N.
        • BP Lowering Treatment Trialists’ Collaboration
        Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overview of randomised trials.
        Lancet. 2000; 356: 1955-1964
        • Lewington S.
        • Clarke R.
        • Qizilbash N.
        • Peto R.
        • Collins R.
        • Prospective Studies Collaboration
        Age-specific relevance of usual BP to vascular mortality: a meta analysis of individual data for one million adults in 61 prospective studies.
        Lancet. 2002; 360: 1903-1913
        • López-Séndon J.
        • Swedberg K.
        • McMurray J.
        • Tamargo J.
        • Maggioni A.P.
        • Dargie H.
        • Tendera M.
        • Waagstein F.
        • Kjekshus J.
        • Lechat P.
        • Torp-Pedersen C.
        Expert consensus document on β-adrenergic receptor blockers.
        Eur Heart J. 2004; 25: 1341-1362
        • Struyker-Boudier H.A.
        • Smits J.F.
        Antihypertensive action of β-adrenoceptor blocking drugs.
        Am J Hypertens. 1989; 2: 237S-240S
        • Pepine C.J.
        • Cohn P.F.
        • Deedwania P.C.
        • Gibson R.S.
        • Handberg E.
        • Hill J.A.
        • Miller E.
        • Marks R.G.
        • Thadani U.
        Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life.
        Circulation. 1994; 90: 762-768
        • von Arnim T.
        Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine.
        J Am Coll Cardiol. 1995; 25: 231-238
        • Fox K.M.
        • Mulcahy D.
        • Findlay I.
        • Ford I.
        • Dargie H.J.
        The Total Ischemic Burden European Trial (TIBET).
        Eur Heart J. 1996; 17: 96-103
        • MERIT-HF Study Group
        Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).
        Lancet. 1999; 353: 2001-2017
        • CIBIS-II Study Group
        The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
        Lancet. 1999; 353: 9-13
        • Packer M.
        • Fowler M.B.
        • Roecker E.B.
        • Coats A.J.
        • Katus H.A.
        • Krum H.
        • Mohacsi P.
        • Rouleau J.L.
        • Tendera M.
        • Staiger C.
        • Holcslaw T.L.
        • Amann-Zalan I.
        • DeMets D.L.
        • Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group
        Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.
        Circulation. 2002; 106: 2194-2199
        • Bonet S.
        • Agusti A.
        • Arnau J.M.
        • Vidal X.
        • Diogene E.
        • Galve E.
        • Laporte J.R.
        β-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients’ characteristics: a meta-analysis of clinical trials.
        Arch Intern Med. 2000; 160: 621-627
        • Castellano M.
        • Bohm M.
        The cardiac β-adrenoreceptor–mediated signaling pathway and its alterations in hypertensive heart disease.
        Hypertension. 1997; 29: 715-722
        • β-Blocker Heart Attack Study Group
        The β-blocker heart attack trial.
        JAMA. 1981; 246: 2073-2074
      1. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction.
        N Engl J Med. 1981; 304: 801-807
        • Freemantle N.
        • Cleland J.
        • Young P.
        • Mason J.
        • Harrison J.
        β Blockade after myocardial infarction: systematic review and meta regression analysis.
        BMJ. 1999; 318: 1730-1737
        • Rizzon P.
        • Di Biase M.
        • Chiddo A.
        • Mastrangelo D.
        • Sorgente L.
        Electrophysiological properties of intravenous metoprolol in man.
        Br Heart J. 1978; 40: 650-655
        • Ellison K.E.
        • Gandhi G.
        Optimising the use of β-adrenoceptor antagonists in coronary artery disease.
        Drugs. 2005; 65: 787-797
        • Tafreshi M.J.
        • Weinacker A.B.
        β-adrenergic-blocking agents in bronchospastic diseases: a therapeutic dilemma.
        Pharmacotherapy. 1999; 19: 974-978
        • Everly M.J.
        • Heaton P.C.
        • Cluxton Jr, R.J.
        β-blocker underuse in secondary prevention of myocardial infarction.
        Ann Pharmacother. 2004; 38: 286-293
        • Dornhorst A.
        • Powell S.H.
        • Pensky J.
        Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.
        Lancet. 1985; 1: 123-126
        • Jacob S.
        • Rett K.
        • Henriksen E.J.
        Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of β-blocking agents?.
        Am J Hypertens. 1998; 11: 1258-1265
        • Giugliano D.
        • Acampora R.
        • Marfella R.
        • De Rosa N.
        • Ziccardi P.
        • Ragone R.
        • De Angelis L.
        • D’Onofrio F.
        Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension.
        Ann Intern Med. 1997; 126: 955-959
        • Bakris G.L.
        • Fonseca V.
        • Katholi R.E.
        • McGill J.B.
        • Messerli F.H.
        • Phillips R.A.
        • Raskin P.
        • Wright Jr, J.T.
        • Oakes R.
        • Lukas M.A.
        • Anderson K.M.
        • Bell D.S.
        • GEMINI Investigators
        Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
        JAMA. 2004; 292: 2227-2236
        • Sarafidis P.A.
        • Bakris G.L.
        Antihypertensive treatment with β-blockers and the spectrum of glycaemic control.
        QMJ. 2006; 99: 431-436
        • Kolendorf K.
        • Jensen H.A.
        • Holst J.J.
        • Poulsen J.E.
        Effect of acute selective β-1-adrenoceptor blockade on hormonal and cardiovascular response to insulin-induced hypoglycaemia in insulin-dependent diabetic patients.
        Scand J Clin Lab Invest. 1982; 42: 69-74
        • Byington R.P.
        • Worthy J.
        • Craven T.
        • Furberg C.D.
        Propranolol-induced lipid changes and their prognostic significance after a myocardial infarction: the β-Blocker Heart Attack Trial experience.
        Am J Cardiol. 1990; 65: 1287-1291
        • Vyssoulis G.P.
        • Karpanou E.A.
        • Pitsavos C.E.
        • Skoumas J.N.
        • Paleologos A.A.
        • Toutouzas P.K.
        Differentiation of β-blocker effects on serum lipids and apolipoproteins in hypertensive patients with normolipidaemic or dyslipidaemic profiles.
        Eur Heart J. 1992; 13: 1506-1513
        • Fogari R.
        • Zoppi A.
        • Corradi L.
        • Preti P.
        • Mugellini A.
        • Lusardi P.
        β-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia.
        J Cardiovasc Pharmacol. 1999; 33: 534-539
        • Hylander B.
        • Eliasson K.
        • Nilsson-Ehle P.
        • Rossner S.
        Effects of long-term therapy with laβlol on lipoprotein metabolism in patients with mild hypertension.
        Acta Med Scand. 1985; 218: 51-54
        • Ko D.T.
        • Hebert P.R.
        • Coffey C.S.
        • Sedrakyan A.
        • Curtis J.P.
        • Krumholz H.M.
        β-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction.
        JAMA. 2002; 288: 351-357
        • Shabsigh R.
        • Perelman M.A.
        • Lockhart D.S.
        • Lue T.F.
        • Broderick G.A.
        Health issues of men: prevalence and correlates of erectile dysfunction.
        J Urol. 2005; 174: 662-667
        • Dusing R.
        Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs.
        Drugs. 2005; 65: 773-786
        • Chen K.
        • Chiou C.F.
        • Plauschinat C.A.
        • Frech F.
        • Harper A.
        • Dubois R.
        Patient satisfaction with antihypertensive therapy.
        J Hum Hypertens. 2005; 19: 793-799
        • Veverka A.
        • Nuzum D.S.
        • Jolly J.L.
        Nebivolol: a third generation β-adrenergic blocker.
        Ann Pharmacother. 2006; 40: 1353-1360
        • Sule S.S.
        • Frishman W.
        Nebivolol.
        Cardiol Rev. 2006; 14: 259-264
        • Van Bortel L.M.
        • Breed J.G.
        • Joosten J.
        • Kragten J.A.
        • Lustermans F.A.
        • Mooij J.M.
        Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life.
        J Cardiovasc Pharmacol. 1993; 21: 856-862
        • Lacourciere Y.
        • Lefebvre J.
        • Poirier L.
        • Archambault F.
        • Arnott W.
        Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination.
        Am J Hypertens. 1994; 7: 137-145
        • Van Nueten L.
        • Taylor F.R.
        • Robertson J.I.
        Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial.
        J Human Hypertens. 1998; 12: 135-140
        • Van Nueten L.
        • Schilling A.
        • Vertommen C.
        • Dupont A.G.
        • Robertson J.I.
        Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomised trial.
        J Hum Hypertens. 1997; 11: 813-819
        • Mazza A.
        • Gil-Extremera B.
        • Maldonato A.
        • Toutouzas T.
        • Pessina A.C.
        Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly.
        Blood Press. 2002; 11: 182-188
        • Grassi G.
        • Trevano F.Q.
        • Facchini A.
        • Toutouzas T.
        • Chanu B.
        • Mancia G.
        Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial.
        Blood Press. 2003; 12: 35-40
        • Czuriga I.
        • Riecansky I.
        • Bodnar J.
        • Fulop T.
        • Kruzsicz E.
        • Edes I.
        • NEBIS Investigators
        Comparison of the new cardioselective β-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS).
        Cardiovasc Drugs Ther. 2003; 17: 257-263
        • Rosei E.A.
        • Rizzoni D.
        • Comini S.
        • Boari G.
        • Nebivolol-Lisinopril Study Group
        Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study.
        Blood Press Suppl. 2003; 1: 30-35
        • Van Bortel L.M.
        • Bulpitt C.J.
        • Fici F.
        Quality of life and antihypertensive effect with nebivolol and losartan.
        Am J Hypertens. 2005; 18: 1060-1066
        • Ambrosini E.
        • Borghi C.
        Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective β-blockers in the treatment of hypertension.
        High Blood Press Cardiovasc Prev. 2005; 12: 27-35
        • Wang T.J.
        • Gona P.
        • Larson M.G.
        • Tofler G.H.
        • Levy D.
        • Newton-Cheh C.
        • Jacques P.F.
        • Rifai N.
        • Selhub J.
        • Robins S.J.
        • Benjamin E.J.
        • D’Agostino R.B.
        • Vasan R.S.
        Multiple biomarkers for the prediction of first major cardiovascular events and death.
        N Engl J Med. 2006; 355: 2631-2639
        • Wald N.J.
        • Law M.R.
        A strategy to reduce cardiovascular disease by more than 80%.
        BMJ. 2003; 326: 14-19
        • Bakris G.L.
        • Hart P.
        • Ritz E.
        β blockers in the management of chronic kidney disease.
        Kidney Int. 2006; 70: 1905-1913
        • Lindholm L.H.
        • Carlberg B.
        • Samuelsson O.
        β blockers in primary hypertension: do age and type of β-blocker matter?.
        J Hypertens. 2006; 24: 2143-2145
        • Ahlquist R.P.
        Present state of alpha- and β-adrenergic drugs I.
        Am Heart J. 1976; 92: 661-664
        • Wikstrand J.
        • Warnold I.
        • Olsson G.
        • Tuomilehto J.
        • Elmfeldt D.
        • Berglund G.
        Primary prevention with metoprolol in patients with hypertension.
        JAMA. 1988; 259: 1976-1982
        • Olsson G.
        • Tuomilehto J.
        • Berglund G.
        • Elmfeldt D.
        • Warnold I.
        • Barber H.
        • Eliasson K.
        • Jastrup B.
        • Karatzas N.
        • Leer J.
        Primary prevention of sudden cardiovascular death in hypertensive patients.
        Am J Hypertens. 1991; 4: 151-158
        • Carlberg B.
        • Samuelsson O.
        • Lindholm L.H.
        Atenolol in hypertension: is it a wise choice?.
        Lancet. 2004; 364: 1684-1689
        • Turner R.C.
        • Cull C.A.
        • Frighi V.
        • Holman R.R.
        • UK Prospective Diabetes Study (UKPDS) Group
        Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49).
        JAMA. 1999; 281: 2005-2012
        • Tzemos N.
        • Lim P.O.
        • MacDonald T.M.
        Nebivolol reverses endothelial dysfunction in essential hypertension.
        Circulation. 2001; 104: 511-514
        • Mason R.P.
        • Kalinowski L.
        • Jacob R.F.
        • Jacoby A.M.
        • Malinski T.
        Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans.
        Circulation. 2005; 112: 3795-3801
        • Peter P.
        • Martin U.
        • Sharmin A.
        • Dunne F.
        Effect of treatment with nebivolol on parameters of oxidative stress in type 2 diabetics with mild to moderate hypertension.
        J Clin Pharm Ther. 2006; 31: 153-159
        • Flather M.D.
        • Shibata M.C.
        • Coats A.J.
        • Van Veldhuisen D.J.
        • Parkhomenko A.
        • Borbola J.
        • Cohen-Solal A.
        • Dumitrascu D.
        • Ferrari R.
        • Lechat P.
        • Soler-Soler J.
        • Tavazzi L.
        • Spinarova L.
        • Toman J.
        • Bohm M.
        • Anker S.D.
        • Thompson S.G.
        • Poole-Wilson P.A.
        • SENIORS Investigators
        Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).
        Eur Heart J. 2005; 26: 215-225
        • Mason R.P.
        • Kubant R.
        • Jacob R.F.
        • Walter M.F.
        • Boychuk B.
        • Malinski T.
        Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: role of antioxidant activity.
        J Cardiovasc Pharmacol. 2006; 48: 862-869
        • Cohn J.N.
        • Archibald D.G.
        • Ziesche S.
        • Franciosa J.A.
        • Harston W.E.
        • Tristani F.E.
        • Dunkman W.B.
        • Jacobs W.
        • Francis G.S.
        • Flohr K.H.
        Effect of vasodilator therapy on mortality in chronic congestive heart failure.
        N Engl J Med. 1986; 314: 1547-1552
        • Celik T.
        • Iyisoy A.
        • Kursaklioglu H.
        • Kardesoglu E.
        • Kilic S.
        • Turhan H.
        • Yilmaz M.I.
        • Ozcan O.
        • Yaman H.
        • Isik E.
        • Fici F.
        Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients.
        J Hypertens. 2006; 24: 591-596
        • Chobanian A.V.
        • Brecher P.
        • Chan C.
        Effects of propranolol on atherogenesis in the cholesterol-fed rabbit.
        Circ Res. 1985; 56: 755-762
        • Grimm Jr, R.H.
        • Grandits G.A.
        • Cutler J.A.
        • Stewart A.L.
        • McDonald R.H.
        • Svendsen K.
        • Prineas R.J.
        • Liebsen P.R.
        • et al.
        • TOMHS Research Group
        Relationships of quality of life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study (TOMHS).
        Arch Intern Med. 1997; 157: 638-648